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Lacking the initial contact between the immune system and microbial-associated molecular patterns (MAMPs), such as
lipopolysaccharides (LPS), early in life, may be regarded as one of the causal factors of the increasing global increase in the
incidence of autoimmune diseases, such as type 1 diabetes (T1D). Previously, a reduced incidence of T1D accompanied by
dramatically increased abundances of both the mucin-metabolising bacterium Akkermansia muciniphila, and LPS-carrying
Proteobacteria was observed, when vancomycin was given to pups of nonobese diabetic (NOD) mice. While the T1D incidence
reducing eﬀect of A. muciniphila has been shown in further studies, little is known as to whether the increased abundance of
LPS-carrying bacteria also has a protective eﬀect. Therefore, we fed NOD pups with Eschericia coli LPS orally from birth to
weaning, which decreased the gene expressions of TNFα, IL-10, IL-6, IFNγ, IL-1β, IL-2, IL-4, and FoxP3 in the pancreatic lymph
nodes, while the same gene expression proﬁle in the spleen was unaﬀected. However, no signiﬁcant diﬀerence in the incidence
of T1D, gut microbiota composition, or ileum expression of the genetic markers of gut permeability, Claudin8, Occludin,
Zonulin-1 (Tjp1), Claudin15, Muc1, and Muc2 were observed in relation to LPS ingestion. It is, therefore, concluded that early
life oral E. coli LPS has an impact on the local immune response, which, however, did not inﬂuence T1D incidence in NOD
mice later in life.
1. Introduction
The hygiene hypothesis proposes early life contact between
microbes and the immune system to be essential for a proper
later life balance between adaptive tolerance and reaction to
inﬂammatory challenges [1]. With some modiﬁcations to
the original hypothesis [2], several studies have strengthened
the idea that the ﬁrst encounter between mucosal surface
proteins and various microorganisms drives both B and T
and particularly regulatory T cell (Treg) expansion [3, 4]. Fail-
ure of this is a likely explanation of the increasing global
increase in the incidence of type 1 diabetes (T1D), multiple
sclerosis, and other autoimmune diseases, as well as asthmas
and allergies [5–9]. In T1D, molecular dysfunctions lead to
the pancreatic inﬁltration with islet antigen-speciﬁc cells
(insulitis), which is initiated by neutrophils, dendritic cells,
and macrophages, and continued with T and B lymphocyte
reactivity, which autonomously attack the insulin-
producing pancreatic beta cells [10]. In humans [8] as well
as in the most common T1D animal model, the nonobese
diabetic (NOD) mouse [10, 11], early-life gut microbiota dys-
biosis seems to have an important inﬂuence on the onset and
progression of T1D [12, 13]. In germ-free NOD mice an
accentuated degree of insulitis, however without a higher
incidence of T1D, has been observed [14], while there are
also reports of the opposite, i.e., unchanged insulitis but a
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higher incidence of T1D in germ-free NOD mice [15].
Therefore, it has been hypothesized by some that only a
very speciﬁc microbiota composition is diabetogenic [16].
Cell walls of various bacteria carry innately immune-
stimulating microbial-associated molecular patterns (MA
MPs), such as lipopolysaccharides (LPS) [17, 18]. When
recognized by Toll-like receptor 4 (TLR4) [19], LPS initially
induces production of inﬂammatory cytokines, e.g., TNFα
and IL-1 [20], and later on interferon β [21] through
nuclear factor κB activation [22]. Recently, we were able
to reduce the T1D incidence by orally feeding the antibiotic
vancomycin to NOD pups from birth to weaning, which
dramatically propagated Verrucomicrobia and Proteobac-
teria, and reduced all other bacterial phyla [23]. The only
Verrucomicrobia genus in mice, Akkermansia muciniphila,
inﬂuences mucosal immune response and degrades the
mucin layer by feeding on mucin [24], while Proteobacteria
contain a high concentration of LPS in its cell walls [8]. The
T1D protective eﬀect of vancomycin [23] could therefore
mechanistically have its background in a combination of
the mucin degrading eﬀect of A. muciniphila and increased
TLR4 stimulation by LPS. Transfer of A. muciniphila from
a low to a high incidence NOD mouse colony delays T1D
development [25], and in streptozotocin diabetic rats, A.
muciniphila supplementation suppresses inﬂammation
[26]. However, monocolonization of A. muciniphila in
germ-free NOD mice has no eﬀect on type 1 diabetes inci-
dence [27] suggesting that the simultaneous presence of
other bacteria, as e.g., the LPS rich Proteobacteria, are nec-
essary for A. muciniphila to exert a protective eﬀect. It has
previously been observed that human T1D patients have
increased levels of serum LPS [28], and that injection of
LPS in the prediabetic phase of NOD mice may delay the
onset of T1D [29]. Early life exposure to LPS and especially
the balance between LPS of Bacteroides and Enterobacteri-
aceae (Proteobacteria) origin is linked to the occurrence
of T1D-associated antibodies in genetically susceptible
human toddlers [8]. Consequently, it is relevant to study,
which impact early-life ingestion of LPS may have on the
pancreatic immune response and T1D development, and
whether LPS can be regarded as a part of a mechanistic
explanation of the protective eﬀect of vancomycin in
NOD mice. As it has been shown that the LPS content of
laboratory rodent diets inﬂuence the development of regu-
latory T cells [4] and consequently has a modest impact
on rodent models of type 2 diabetes [30], it may also be rel-
evant to elucidate whether it inﬂuences the NOD mouse as
a model for T1D. We, therefore, hypothesized that admin-
istration of LPS in early life would reduce proinﬂammatory
gene expression in the pancreatic lymph node (PLN) and
subsequently T1D incidence in NOD mice.
2. Material and Methods
2.1. Mouse Experiments. Experiments were approved by the
Animal Experiments Inspectorate, Ministry of Environment
and Food, Denmark (License 2012-15-2934-00256–C1) in
accordance with the EU Directive 2010/63/EU on the Protec-
tion of Vertebrate Animals used for Experimental and Other
Scientiﬁc Purposes and the Danish Animal Experimentation
Act (LBK 474 from 15/05/2014). 40 (18 female and 22 male)
C57BL/6NTac (B6) and 34 female NOD/MrkTac mice were
bred in-house on breeding pairs purchased from Taconic
(Germantown, USA) and housed in our AAALAC-
accredited barrier-protected and microbiologically moni-
tored [31] facility with a 12-hour light-time schedule, in open
cages with ad libitum food and water access. Puriﬁed E. coli
0127: B8 LPS (Sigma-Aldrich, Brøndbyvester, Denmark)
was diluted in phosphate-buﬀered saline (PBS) (0.2mg/mL)
and administered orally with a pipette every other day from
birth till four weeks of age with 10μl and 20μl pr. mouse
(B6: n = 18 and NOD: n = 11) for the ﬁrst two and the last
two weeks, respectively. An equal dose of PBS was adminis-
trated to the control mice (B6: n = 22 and NOD: n = 23).
All mice were monitored for overall well-being throughout
the study and weighed weekly. At four weeks of age, the B6
mice were weighed and anaesthetized with Hypnorm (fenta-
nyl andﬂuanisone, VetaPharma, Leeds, England) andDormi-
cum (midazolam, F. Hoﬀmann-La Roche, Basel, Switzerland)
dosed subcutaneously with 0.5mL/100 g of body weight as a
1 : 1 : 2 aqueous solution. The total blood volume was col-
lected from the retro-orbital plexus into sterile Eppendorf
tubes (Eppendorf, Germany), and blood was stored on ice
for approximately one hour before being centrifuged (500 x
g, 10min). Hereafter, the mice were sacriﬁced by cervical dis-
location prior to harvesting feces, the pancreatic lymph
nodes (PLN), the spleen, and the ileum. Samples were stored
at -80°C until analysed. Tail-vein blood glucose was moni-
tored in NODmice weekly until 30 weeks of age, and a blood
glucose value of ≥12mmol on two consecutive measure-
ments was diagnosed as T1D. If their overall condition was
deteriorating, they were euthanized.
2.2. Analyses. LPS concentration in serum was analysed using
a Limulus Amebocyte Lysate (LAL) chromogenic endpoint
assay for endotoxin detection (HIT302 edition 10-16, Hycult
Biotech, Netherlands). The samples were diluted 1 : 10, run in
duplicates, with an extra control sample with no LAL reagent
added. Samples were analysed according to the manufac-
turer’s instructions, with the addition of a heating step
(70°C for 5min) prior to adding the samples to the wells, to
neutralize endotoxin inhibiting compounds.
Total fecal bacterial DNA was extracted using the Power-
Soil® DNA Isolation Kit (MO BIO Laboratories, Carlsbad,
CA), following the instructions of the manufacturer with
minor modiﬁcations. Samples were placed into the Power-
Bead tubes and heat-treated at 65°C for 10min and then at
95°C for 10min prior DNA extraction. Subsequently, solu-
tion C1 was added and bead-beating performed in FastPrep
(MP Biomedicals, Santa Ana, CA, USA) using 3 cycles of
15 s each, at a speed of 6.5ms. The gut microbiota composi-
tion was determined using tag-encoded 16S rRNA gene
(V3-V4 regions) MiSeq-based (Illumina, San Diego, CA)
high-throughput sequencing. DNA extraction, storage con-
ditions, and sequencing library preparation were all con-
ducted as previously described [32].
Gene expressions of the spleen, pancreatic lymph nodes
(PLN), and ileum were analysed by quantitative PCR
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(qPCR). Samples were homogenized with FastPrep in
500μl lysis buﬀer MagMAX™-96 Total RNA Isolation Kit
(AM1830, Thermo Fisher Scientiﬁc, Herlev, DK) with
0.7% β-mercapthoethanol and glass beads and then stored
at -20°C prior to RNA puriﬁcation (AM1830, and Mag-
MAX™ Express magnetic particle processor, Thermo
Fisher). cDNA synthesis, qPCR, and data management
were performed as described previously [33], i.e., the
expression of target genes were normalized to the reference
gene Actinβ, (ΔCT = CT target – CT ref erence ). Fold change in
gene expression was calculated as 2-ΔΔCT, where ΔΔCT =
ΔCT sample − ΔCT calibrator and where the mean ΔCT of
samples from the control mice was used as a calibrator.
Genes analysed in the spleen and PLN were IL-18, TNFα,
IL-10, IL-6, IFNγ, IL-1β, IL-12β, IL-5, IL-2, IL-4, IL-17α,
and Foxp3. Genes analysed in the ileum were Claudin8,
Occludin, Zonulin-1 (Tjp1), Claudin15, Muc1, and Muc2.
2.3. Statistical Analyses. Comparisons of relative gene expres-
sion levels were done with one-tailed Student’s t-test, if
d’Agostino-Pearson test showed a Gaussian distribution,
and F-test showed equal variances, and if not with one-
tailed Mann-Whitney test, and analysis of interference by
sex (B6 mice), was done by applying a two-way ANOVA.
Cumulative diabetes incidence was calculated using the
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Figure 1: Cytokine and regulatory T cell (FoxP3) gene expressions in the pancreatic lymph nodes (PLN) of 40 (18 female and 22 male)
four-week-old C57BL/6NTac mice given either LPS (n = 18) or PBS (n = 22) orally daily from birth until weaning at four weeks of age.
Mean and SD are shown. ∗p < 0 05; ∗∗p < 0 01; ∗tendency p = 0 05 – 0 1.
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Kaplan–Meier estimation, while statistical signiﬁcance was
evaluated by the logrank test. All statistical tests were done
with GraphPad Prism 7.0 (GraphPad Software, La Jolla,
USA). For gut microbiota characterisation, Illumina MiSeq-
platform generated 16S rRNA gene amplicons (V3-V4re-
gions) were analysed as previously described [34].
3. Results
3.1. LPS Inﬂuences Inﬂammatory State in the PLN in B6Mice,
While It Does Not Inﬂuence the T1D Incidence in NOD Mice.
The immune stimulatory eﬀect of LPS from birth to four
weeks of age was investigated by measuring the relative gene
expression of cytokines in B6 mice at four weeks of age. In the
PLN, LPS administration signiﬁcantly decreased the expres-
sion of the majority of pro- and anti-inﬂammatory cytokine
genes analysed, i.e., IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12β,
TNFα, IFNγ, and FoxP3 (Figure 1). For IL-1β, IL-2, IL-4,
IL-6, IL-10, IL-12β, TNFα, IFNγ, and FoxP3, the control
groups had a signiﬁcantly larger interindividual variation
(Figure 1). Sex had no signiﬁcant impact. LPS did not seem
to have a strong inﬂuence on the systemic level of
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Figure 2: Cytokine and regulatory T cell (FoxP3) gene expressions in the spleen of 40 (18 female and 22 male) four-week-old C57BL/6NTac
mice given either LPS (n = 18) or PBS (n = 22) orally daily from birth until weaning at four weeks of age. Mean and SD are shown. ∗∗p < 0 01;
∗tendency p = 0 05 – 0 1.
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inﬂammation, as only IL-18 was signiﬁcantly downregulated
in the spleen, while there was a tendency towards downregu-
lation of FoxP3 and TNFα . However, as it was the case in
PLN, IL-12β, IL-18, TNFα, and FoxP3 (p = 0 0019) also
expressed a higher variation in the spleens of the control
groups (Figure 2).
75% of NOD mice, which had received oral LPS for the
ﬁrst four weeks of life developed T1D compared to 68% of
the PBS-treated control mice (Figure 3), which was not sig-
niﬁcantly diﬀerent. NOD mothers of the pups on LPS treat-
ment appeared to become diabetic faster and then being
less able to take care of their pups, resulting in small pups,
which in some cases had to be euthanized for humane rea-
sons. Three moms in the LPS group had to be euthanized
or died prior to weaning of the pups, while there were no
such incidences in the PBS group.
3.2. In the Gut of B6 Mice, Prevotella Spp. Were
Downregulated after LPS Administration, While Permeability
Was Not Inﬂuenced. LPS administration did not induce any
signiﬁcant diﬀerence in the overall gut microbiota composi-
tion (Figure 4). The abundances of some genera were
inﬂuenced by the LPS (Table 1), but among these, only Prevo-
tella spp. were observed with a high abundance, i.e., 11.2% in
the PBS-treated control mice, while only 5.7% in the LPS-
treatedmice (Table 1). There were no indications of increased
amounts of LPS entering the blood stream, as LPS-
administered mice did not have more LPS in serum than the
controlmice (data not shown),which alsomatched theﬁnding
that noneof the geneticmarkers of gut permeability,Claudin8,
Occludin, Zonulin-1 (Tjp1),Claudin15,Muc1, andMuc2were
expressed diﬀerently in the ileum in relation to LPS adminis-
tration (data not shown).
4. Discussion
As hypothesized, administration of LPS in early life reduced
both anti- and proinﬂammatory cytokine gene expressions
in PLN. The impact was far less or absent in the spleen, which
indicates that the eﬀect of LPS is local and not systemic, sup-
porting previous observations on bacterially derived activa-
tion of the immune system [35]. This also matches the fact
that there was not a surplus of LPS which entered the blood
stream due to the LPS administration, and that gut perme-
ability was unchanged. An increased inﬂamed milieu in the
PLN has been observed prior to onset of insulitis [36], which
is considered important for the attraction and activation of
the autoreactive T cells that circulate in the host thereby ini-
tiating the T1D development [37]. Such local eﬀects of LPS
on the cytokine milieu in the PLN, with no systemic indica-
tion, require a homing speciﬁcally to the PLN, as it has been
proposed previously [38]. It is likely that LPS has the poten-
tial to halter production of inﬂammatory cytokines in the
PLN through homing receptors [35]. LPS is known to pro-
mote the secretion of several inﬂammatory cytokines (IL-1,
TNFα, IFN-α, IL-12, IL-15, and IL-18) [39, 40], which to a
certain extent are the same cytokines regulated by those
genes that we observed downregulated in the PLN after LPS
administration. Also, the LPS receptor TLR4 has previously
been correlated with increased levels of IL-1β and TNFα in
T1D patients [41]. This may seem contradictory, but it is
the concept of the hygiene hypothesis that early-life inﬂam-
matory stimulation on a long-term basis activates more
regulatory than inﬂammatory immunity, which is also
observed in the low-dose dextran sodium sulphate (DSS)
model [42, 43]. So, the timing and dose of LPS exposure is
important, indicating a “window of opportunity” for eliciting
a protective eﬀect of LPS.
We monitored inﬂammatory parameters after four weeks
of dosing. Obviously, we do not know how early before that
the eﬀect would have been measurable. However, in a previ-
ous study on older diet-induced obese mice, we were unable
to register any impact after only two weeks of oral LPS dosing
[30]. It is also apparent from the present and previous studies
in the low-dose DSS model that such an early-life inﬂamma-
tory stimulation does not necessarily have major preventive
impact on the development of T1D [29, 44], although one
study showed a delayed onset if LPS was injected in the pre-
diabetic phase [29]. As an early-life DSS treatment alleviates
symptoms of oxazolone-induced colitis in mice [43], which,
in contrast to the Th1 dominated T1D, is dominated by
Th2 cells, eventually the LPS eﬀect could be based upon a
shift in cell type balance. This is, however, not indicated by
our study, as those genes for which the expression was down-
regulated in PLN were related to diﬀerent types of T cells. It
has previously been observed that human T1D patients have
increased levels of serum LPS [28], i.e., while early-life LPS
may induce regulatory immunity later in life, LPS stimulation
later in life may favour development of inﬂammatory and
autoimmune disease, such as T1D. As injection of LPS in
the prediabetic phase of NODmice seemed to delay the onset
of T1D in another study [29], it is diﬃcult to say when the
window for a regulatory eﬀect of LPS closes.
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Figure 3: Incidence of type 1 diabetes diagnosed as three
consecutive blood values of glucose >12mmol/l in NOD/MrkTac
mice given either LPS (n = 18) or PBS (n = 22) orally daily from
birth until weaning at four weeks of age and observed until 30
weeks of age.
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The LPS of Bacteroidetes has been found to have severely
impaired capacity for immune stimulation relative to LPS
from Enterobacteriaceae [8]. A key diﬀerence between Finn-
ish and Estonian children with a high T1D incidence from
Russian children with a low T1D incidence is that much of
the gut LPS in the Finnish and Estonian children is Bacteroi-
detes-derived, while in the Russian children it derives from E.
coli (Proteobacteria) [8]. Notably, our oral administration of
LPS had only minor inﬂuences on GM composition. The
abundance of Bacteroides spp. was low in both groups, while
S24-7 belonging to Bacteroidales was high in both groups,
but none of them diﬀered between the groups. Prevotella also
belongs to the phylum Bacteroidetes, and it was observed to
be signiﬁcantly decreased in the gut of mice having received
oral LPS, indicating that the LPS dose may have had a sup-
pressing eﬀect on this particular genus. It is also striking that
the Betaproteobacteria-containing families, such as Entero-
bacteriaceae, was below the detection level in all mice, i.e.,
the endogenic level of E. coli LPS was very low, indicating
that the NODmice more resemble the Finnish/Estonian chil-
dren than the Russian children.
It is of course of interest that NOD mothers of the pups
on LPS treatment appeared to become diabetic faster than
mothers of PBS-treated mice. The most reasonable explana-
tion is that they received an LPS dose from their pups. It is
diﬃcult to state, how much this has been. In studies of acute
inﬂammation, mice are dosed with up to 10mg/kg LPS intra-
peritoneally [45], and for the moms to get this dose from
their pups, they should more or less have eaten everything
which was dosed to their pups, which would not be possible.
However, much lower doses are known to induce low-grade
inﬂammation in mice [46]. The unintended dosing of the
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mothers in our study has been oral, and in a previous study,
we did not observe dramatic inﬂammatory responses after a
low oral dose of LPS [30]. On the other hand, it cannot be
excluded that some of the eﬀects we observed in the pups
of the present study were transferred from the mother and
were caused by her ingestion of LPS.
In summary, our results demonstrate that although LPS
dosing in early life has an impact on the cytokine expressions
in the PLN, this was, in this study, not suﬃcient or of a kind
that inﬂuenced T1D incidence in NOD mice later in life.
Therefore, even though vancomycin leads to dramatically
increased abundances of both A. muciniphila and LPS-
carrying Proteobacteria [23], the protective eﬀect in relation
to T1D in NOD mice is more likely to be related to A. muci-
niphila, while puriﬁed E. coli 0127: B8 LPS, as used in this
study, probably does not play a major role. This is in accor-
dance with recent observations that the sole presence of A.
muciniphila in the microbiota of a colony of T1D prone
NOD mice can decrease the incidence of T1D [25].
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